Acumen Pharmaceuticals (ABOS) Financials

As of fiscal year 2025, Acumen Pharmaceuticals, Inc. (ABOS) had $54.0M in cash and equivalents against $22.4M in long-term debt.

Acumen Pharmaceuticals, Inc. (ABOS) has a return on equity of -172.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Acumen Pharmaceuticals, Inc. (ABOS) recorded an outflow of $115.6M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Acumen Pharmaceuticals, Inc. (ABOS) recorded an outflow of $115.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Acumen Pharmaceuticals, Inc. (ABOS) had $122.8M in total assets as of fiscal year 2025, including both current and long-term assets.

Acumen Pharmaceuticals, Inc. (ABOS) invested $88K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Acumen Pharmaceuticals, Inc. (ABOS) invested $104.9M in research and development during fiscal year 2025.

Acumen Pharmaceuticals, Inc. (ABOS) had 72M shares outstanding as of fiscal year 2025.

Acumen Pharmaceuticals, Inc. (ABOS) had a current ratio of 4.07 as of fiscal year 2025, which is generally considered healthy.

Acumen Pharmaceuticals, Inc. (ABOS) had a debt-to-equity ratio of 0.32 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Acumen Pharmaceuticals, Inc. (ABOS) had a liabilities-to-equity ratio of 0.74 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Acumen Pharmaceuticals, Inc. (ABOS) had a return on assets of -98.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Acumen Pharmaceuticals, Inc. (ABOS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $165.6M as of Oct 29, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Acumen Pharmaceuticals, Inc. (ABOS) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $165.6M as of Oct 29, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Acumen Pharmaceuticals, Inc. (ABOS) held $116.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $115.5M over that year. Dividing the one by the other, the reported balance equals about 12 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Acumen Pharmaceuticals, Inc. (ABOS) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Acumen Pharmaceuticals, Inc. (ABOS) reported a net loss of $121.3M while operations used $115.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Acumen Pharmaceuticals, Inc. (ABOS) reported an operating loss of $123.8M against $4.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.